Trial Profile

Efficacy and Safety of Aflibercept in Combination With FOLFIRI Chemotherapy as 1st Line Treatment for Patients With Metastatic Colorectal Cancer

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 29 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aflibercept (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary)
Indications Adenocarcinoma; Colorectal cancer
Focus Therapeutic Use
Acronyms FFCD1302

Most Recent Events

23 Oct 2018 The study was stopped at the first stage, as reported in an abstract presented at the 43rd European Society for Medical Oncology Congress
26 May 2016 Planned primary completion date changed from 1 Feb 2016 to 1 Feb 2017.
23 Dec 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com